



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/876005/2022

European Medicines Agency decision P/0541/2022

of 30 December 2022

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMA-001501-PIP04-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0541/2022

of 30 December 2022

on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (Dupixent), (EMA-001501-PIP04-19-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0059/2020 issued on 10 February 2020, and decision P/0361/2021 issued on 8 September 2021,

Having regard to the application submitted by Regeneron Ireland DAC on 8 August 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 November 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dupilumab (Dupixent), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/0169/2014 issued on 8 July 2014, including subsequent modifications thereof.

Article 3

This decision is addressed to Regeneron Ireland DAC, One Warrington Place, D02 HH27 – Dublin, Ireland.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/687759/2022
Amsterdam, 11 November 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001501-PIP04-19-M02

Scope of the application

Active substance(s):

Dupilumab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of eosinophilic esophagitis

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Regeneron Ireland DAC

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Regeneron Ireland DAC submitted to the European Medicines Agency on 8 August 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0059/2020 issued on 10 February 2020, and decision P/0361/2021 issued on 8 September 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 12 September 2022.



Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of eosinophilic esophagitis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- solution for injection, subcutaneous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of eosinophilic esophagitis

2.1.1. Indication(s) targeted by the PIP

Treatment of eosinophilic esophagitis (EoE)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1 (R668-EE-1774) Double-blind, randomised, placebo-controlled trial to evaluate safety and efficacy of dupilumab as add-on to best standard of care compared to placebo in children from 12 to less than 18 years of age (and adults) with eosinophilic esophagitis

	Study 2 (R668-EE-1877) Double-blind, randomised, placebo-controlled trial to evaluate PK, safety and efficacy of dupilumab as add-on to best standard of care compared to placebo in children from 2 to less than 12 years of age with eosinophilic esophagitis
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of atopic dermatitis

Authorised indication(s):

Adults and adolescents

- Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Children 6 to 11 years of age

- Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

2. Treatment of asthma

Adults and adolescents

- Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO (see section 5.1), who are inadequately controlled with high dose ICS plus another medicinal product for maintenance treatment.

Children 6 to 11 years of age

- Dupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

3. Treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP)

- Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Subcutaneous use